Who Paid My Doc
A Phase 3 Long-Term Safety Extension Study of Shp647 in Subjects With Moderate to Severe Ulcerative Colitis (Aida)
ClinicalTrials.gov NCT03283085
Research payments
$1,174,753
Through program year 2025, $1,174,753 in research payments was reported against A Phase 3 Long-Term Safety Extension Study of Shp647 in Subjects With Moderate to Severe Ulcerative Colitis (Aida), across 497 payments, paid by Takeda Pharmaceuticals U.S.A., Inc..
- Paid by
- Takeda Pharmaceuticals U.S.A., Inc.
- ClinicalTrials.gov
- NCT03283085
By program year
5 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2025 | Research | $8,611 | 17 |
| 2024 | Research | $216,142 | 101 |
| 2023 | Research | $257,010 | 84 |
| 2022 | Research | $224,570 | 107 |
| 2021 | Research | $468,420 | 188 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
9 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- Kwabena Ayesu Orlando, FL Named on 50 payments
- Jeff Bullock San Antonio, TX Named on 37 payments
- Mark Fleisher Jacksonville, FL Named on 33 payments
- Ronald Fogel Chesterfield, MI Named on 30 payments
- Khurram Baig Winchester, VA Named on 24 payments
- Fred Rosenberg Gurnee, IL Named on 23 payments
- Jatinder Pruthi Lancaster, CA Named on 20 payments
- Gil Fernandez-Yera Miami, FL Named on 18 payments
- Pradeep Bekal Cincinnati, OH Named on 15 payments
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.